Академический Документы
Профессиональный Документы
Культура Документы
10 Favorite
Low-Priced
Stocks
for
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970
Cabot’s 10 Favorite Low-Priced Stocks for 2018
BIG PROFITS IN LOW-PRICED STOCKS ... IF YOU KNOW HOW TO HANDLE THEM
By Michael Cintolo, Cabot Vice President of Investments
We’ve been refining our growth stock methodology since Cabot Growth Investor was launched
back in 1970, and one of its key tenets is to avoid the junk stocks … which usually means the
low-priced, thinly-traded stocks that have little chance of attracting much in the way of
institutional support (and thus, little chance of enjoying sustained uptrends).
But we’re nothing if not pragmatists, and after lots of research and experience, we’ve found that
many thinner, lower-priced names do have a place in your portfolio—but only if you enter at the
right time, and look to take short-term profits on pops. After further testing and trial runs, we
launched our annual Cabot’s 10 Favorite Low Priced Stock report back in 2003.
The report takes advantage of two trends. The first (and most commonly talked about) is tax-
loss selling, which tends to drive down many stocks and sectors (especially those that have
performed poor during the year) in mid- to late December. The second factor is simply the
market’s pattern of performing well around the holidays and into the middle of January (and
sometimes longer). We call this the “euphoria effect,” with sellers usually putting up little in the
way of resistance to higher prices, allowing some low-priced names to tack on great gains.
Because of the great market advance this year, you’d think there would be few stocks scraping
multi-year lows. But it turns out there are plenty of areas that were poor performers for much of
the year, and have only recently found buyers. This year’s list has a bunch of these turnaround-
type situations—babies that were tossed out with their sector’s bathwater during the year, but
now look ready to (and often have begun to) bounce back.
Just as important as what to buy is having a plan on how to handle these stocks. Here are a few
guidelines.
First, don’t invest the rent money. Obviously, we think these stocks have potential, but
they’re not the institutionally-owned liquid leading stocks we usually recommend. They’re
on the speculative side of the equation, so keep your positions small. And don’t place orders
overnight, which often results in a bad buy price
Second, be sure to cut all losses short, usually near 20% (though we suggest more specific loss
limits inside). Even in shorter-term trading, the market is a game of outliers, so work hard to
make sure none of these stocks get away from you on the downside.
Third, look to sell some or all of your shares offensively, i.e., on the way up. These
recommendations aren’t meant as long-term holds, though some can perform well for many
months if things go right. We’re aiming for a swing trade usually between three and eight weeks.
So if you get a quick gain of 10% to 20%, consider taking at least some (if not all) of your position
off the table.
Fourth, if you’re more aggressive, you can sell some shares (say, one-third to one-half) on the
way up, and then trail a mental stop on the rest of your position (starting from breakeven) in an
effort to capture a longer-term move. Such a method will allow you to have your cake (booking
a small profit when the stock pops higher) and eat it too (if the stock continues rising for many
weeks or even months).
All in all, what really counts is having and sticking to a sound game plan. While we will not
provide regular updates on these stocks (this is a one-time report), we are here to help, so feel
free to email me directly at mike@cabotwealth.com with questions or comments. Good luck!
Prices as of December 14, 2017.
Cabot’s Low-Priced Stock Report
December 2017 3
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 5
In terms of content, the new management team has Right now, a big driver of business is its Design Home
shifted the company’s focus away from celebrity- game, which, like most, is free to download but has a ton
focused games and toward creative games that of things to buy once you start playing. Design Home
have “new” events and attractions that generate a allows users to unleash their inner interior designer,
continuing stream of revenue and bookings. (The decorating digital houses with various high-end brands
typical game gets most of its bookings right after and joining a creative community that helps everyone
the launch, and then dies off fairly quickly. Glu’s learn about diverse décor styles. Glu believes this
“evergreen” titles, which are updated frequently and has become a lifestyle app of sorts—it has more than
offer special attractions to keep interest up, tend to one million daily active users and is one of the top 20
slowly grow over time, with their highest levels of grossing games on the U.S. iTunes app store.
bookings achieved more than 18 months after launch.
Operationally, there’s also been some belt tightening
on spending, along with improved marketing (user
acquisition costs have been falling) with management
Glu Mobile (GLUU) putting an emphasis on actual profits for shareholders.
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 6
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 7
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 8
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 9
The big idea revolves around a drug called It turned out that about 30% of patients
Fostamatinib, which is an oral SYK inhibitor (able responded to Fostamatinib, and encouragingly,
to inhibit incorrect immune responses by the most of those that did respond saw their platelets
body) that Rigel is researching for a few different spike to well above 50,000 (where clotting can
diseases. But the treatment the market is focused occur) within a couple of weeks. In other words,
on most is for idiopathic thrombocytopenic Fostabmatinib usually works quickly, and if it
purpura (ITP), a disease where the body’s own doesn’t, a doctor can quickly switch to a different
immune system destroys its platelets, leading to treatment.
an inability to clot and other side effects.
A 30% response might not sound like much,
ITP is very rare, affecting just 65,000 adults in the but these were severe cases and the FDA is
U.S., and it’s proven tough to treat—some people clearly impressed. Rigel submitted a new drug
respond to treatments but others don’t, leading application earlier this year, and on October 2,
to a long/expensive trial-and-error process. the FDA announced that it’s not planning to hold
But Rigel has gone through the testing process a specific committee meeting. Investors read
treating chronic and persistent ITP patients with that as meaningfully raising the odds of a full-
Fostamatinib—and the results were great! out approval no later than April 2018. That news
caused the stock to skyrocket, with investors
Rigel Pharmaceuticals (RIGL) thinking a commercial launch is very likely in the
second quarter of next year.
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 10
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 11
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com
Cabot’s Low-Priced Stock Report
December 2017 12
That’s a massive opportunity, and through product Better yet, the stock has shown unusual strength
innovation and selective acquisitions, it’s the reason recently after a solid Q3 report, the acquisition of
USA Technologies has a bright future. The company Cantaloupe and raised guidance for the coming
has an end-to-end solution (dubbed ePort Connect) quarters—management expects revenues to grow
that includes the hardware that serves as the user another 35% this year, while analysts see earnings of
interface and allows swipeless payments, including tripling to 18 cents per share.
Google and Apple Pay. It also has blue-chip payment
deals galore with the likes of MasterCard, Chase, The stock had a choppy run to nearly 6 in September
Samsung Pay, Verizon and more. 2016, then began to build a long launching pad. In
mid-October of this year, USAT was still hanging
There’s also software that processes transaction and around 6, but since then, we’ve seen a real character
provides real-time sales and inventory data, which change, as shares nearly rallied to 9 in a straight
leads to huge productivity gains for operators. USA line on excellent volume (10 of 11 days were up on
also allows for additional services like coupons, very strong volume. And now, USAT has tightened
loyalty rewards and even digital advertising. up in the mid-8s, consolidating its gains. We love the
potential here. A stop near the 50-day line (7.4) is
It’s a simple-but-powerful growth story, and USA advised.
Technologies has done a great job of grabbing and
maintaining a dominant position in the industry. At USA Technologies (USAT)
the end of the third quarter, it had nearly 600,000
connections (up 26,000 from the prior quarter),
leading the industry by a good margin. And now it’s
going for the jugular! In November, it announced the
acquisition of Cantaloupe Systems, which brings
with it a highly complimentary client base, dynamic
route scheduling and inventory management
capabilities, as well as another 250,000 or so
connections.
Cabot Wealth Network • 176 North Street • P.O. Box 2049 • Salem, MA 01970 • 978-745-5532 • https://cabotwealth.com